Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Insider Transactions

Date Name Title Type Shares Traded Price Range
Apr 29, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 50 $2.44
Apr 29, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 1,566 $2.43
Apr 29, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 600 $2.39
Apr 29, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 400 $2.40
Apr 29, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 400 $2.40
Apr 29, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 42,084 $2.42
Apr 23, 2009
Vice President Finance
Vice President Finance Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 50,000 $1.15
Apr 23, 2009
Vice President Finance
Vice President Finance Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 75,000 $1.15
Apr 23, 2009
Vice President Finance
Vice President Finance Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 50,000 $1.15
Apr 23, 2009
Vice President Finance
Vice President Finance Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 100,000 $1.15
Apr 23, 2009
Vice President Finance
Vice President Finance Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 75,000 $1.15
Apr 23, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 10,000 $0.01
Apr 23, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 600 $0.01
Apr 23, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 500,000 $1.15
Apr 23, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 3,000 $0.01
Apr 23, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 8,000 $0.01
Apr 23, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 3,000 $0.01
Apr 23, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 450,000 $1.15
Apr 23, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) 300,000 $1.15
Jan 16, 2009
Vice President Finance
Vice President Finance Grant, award or other acquisition pursuant to Rule 16b-3(d) 50,000 $1.47
Jan 16, 2009
Director, Chairman, CEO & President
Director, Chairman, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 350,000 $1.47
Dec 31, 2008
Director, Chairman, CEO & President
Director, Chairman, CEO & President Bona fide gift 12,370 $1.94
Dec 06, 2008
Vice President Finance
Vice President Finance Grant, award or other acquisition pursuant to Rule 16b-3(d) 50,000 $1.43
Dec 06, 2008
Vice President Finance
Vice President Finance Grant, award or other acquisition pursuant to Rule 16b-3(d) 30,000 --
Dec 06, 2008
Director, Chairman, CEO & President
Director, Chairman, CEO & President Grant, award or other acquisition pursuant to Rule 16b-3(d) 200,000 --

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Copyright West LLC. Minimum 15 minutes delayed.